Previous Page   Next Page

The content of this section has been developed in collaboration between COR2ED GmbH (an Independent Medical Education Company) and the experts serving as Scientific Directors on this programme:

  • Prof Simon Boulton (The Francis Crick Institute, London; and Artios Pharma Ltd., Cambridge, UK),
  • Dr Judith Balmaña (Vall d’Hebron Institute of Oncology, and Vall d’Hebron University Hospital, Barcelona, Spain),
  • Prof Charlie Gourley (Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, UK),
  • Dr Violeta Serra (Vall d’Hebron Institute of Oncology, Barcelona, Spain).

The Scientific Directors thank Dr Neal Shore (Carolina Urologic Research Center and Atlantic Urology Clinics, LLC, Myrtle Beach, SC, United States) for his input.

Medical writing support was provided by Alison Comer, PhD, and Mark English, PhD, of COR2ED GmbH. Subsequently the content was donated to the European Society for Medical Oncology (ESMO).

ESMO, COR2ED GmbH and the Scientific Directors wish to thank AstraZeneca for their support with an independent sponsorship grant. Within the context of this independent sponsorship grant AstraZeneca had no influence over the content

ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.

Last update: 25 July 2019